Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
Pulmonx (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has scheduled its Q2 2025 financial results announcement for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live and archived webcast through the company's investor relations website.
Pulmonx (NASDAQ: LUNG), azienda leader nei trattamenti minimamente invasivi per le malattie polmonari, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 30 luglio 2025, dopo la chiusura del mercato. La direzione terrà una conference call alle 13:30 PT / 16:30 ET per discutere i risultati. Gli investitori potranno seguire la trasmissione in diretta e l'archivio webcast tramite il sito web delle relazioni con gli investitori della società.
Pulmonx (NASDAQ: LUNG), líder en tratamientos mínimamente invasivos para enfermedades pulmonares, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el 30 de julio de 2025, tras el cierre del mercado. La dirección realizará una llamada conferencia a las 1:30 PM PT / 4:30 PM ET para comentar los resultados. Los inversores podrán acceder a la transmisión en vivo y al archivo webcast a través del sitio web de relaciones con inversores de la compañía.
Pulmonx (NASDAQ: LUNG)는 최소 침습 폐 질환 치료 분야의 선두 기업으로, 2025년 2분기 재무 결과 발표를 2025년 7월 30일 시장 마감 후에 예정하고 있습니다. 경영진은 결과를 논의하기 위해 오후 1:30 PT / 오후 4:30 ET에 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 생중계 및 아카이브 웹캐스트에 접속할 수 있습니다.
Pulmonx (NASDAQ : LUNG), un leader dans les traitements pulmonaires peu invasifs, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le 30 juillet 2025, après la clôture du marché. La direction tiendra une conférence téléphonique à 13h30 PT / 16h30 ET pour discuter des résultats. Les investisseurs pourront accéder au webcast en direct et à l’archive via le site des relations investisseurs de la société.
Pulmonx (NASDAQ: LUNG), ein führendes Unternehmen für minimalinvasive Behandlungen von Lungenerkrankungen, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 30. Juli 2025 nach Börsenschluss geplant. Das Management wird um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können den Live-Stream und das Archiv über die Investor-Relations-Website des Unternehmens verfolgen.
- None.
- None.
REDWOOD CITY, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Wednesday, July 30, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraXTM Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraXTM is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will Pulmonx (LUNG) release Q2 2025 earnings?
What time is the Pulmonx (LUNG) Q2 2025 earnings call?
How can I access Pulmonx (LUNG) Q2 2025 earnings call?
What does Pulmonx (LUNG) company do?
